Core Insights - The Zacks Equity Research team has highlighted several stocks, including AbbVie Inc., RTX Corp., International Business Machines Corp., EVI Industries, Inc., and Rocky Mountain Chocolate Factory, Inc. in their Analyst Blog [1][2] AbbVie Inc. (ABBV) - AbbVie shares have increased by 13.8% over the past six months, while the Zacks Large Cap Pharmaceuticals industry has gained 29.5% [4] - The company exceeded fourth-quarter estimates for both earnings and sales, successfully managing the loss of exclusivity for Humira by launching new immunology drugs, Skyrizi and Rinvoq, which are performing well [4][5] - AbbVie's neuroscience portfolio is also contributing to revenue growth, with robust net sales growth reported in 2025, marking the second full year post-Humira's loss of exclusivity [5] RTX Corp. (RTX) - RTX shares have outperformed the Zacks Aerospace - Defense industry, gaining 29.2% compared to 11.7% over the past six months [6] - The company reported fourth-quarter earnings and revenues that surpassed estimates, benefiting from strong orders for defense products from the Pentagon and foreign allies [6][7] - RTX's backlog reached $268 billion as of December 31, 2025, supported by improving global commercial air traffic [8] International Business Machines Corp. (IBM) - IBM shares have risen by 10.8% over the past six months, while the Zacks Computer - Integrated Systems industry has gained 61.4% [9] - The company reported strong fourth-quarter results, with adjusted earnings and revenues exceeding estimates, driven by growth in hybrid cloud, AI-powered automation, and enterprise consulting [9][10] - IBM is focusing on its Watsonx platform for AI capabilities and quantum technology, although it faces challenges from traditional business weaknesses and high debt levels [11] EVI Industries, Inc. (EVI) - EVI shares have outperformed the Zacks Industrial Services industry, increasing by 24.4% over the past year [12] - The company reported a 24% revenue increase in the December quarter and a 20% rise for the first six months of FY26, with gross margin expanding to approximately 31% [12][13] - Despite solid revenue growth, net income has dipped due to rising SG&A expenses, and the company faces increased working capital demands [14] Rocky Mountain Chocolate Factory, Inc. (RMCF) - Rocky Mountain shares have outperformed the Zacks Retail - Restaurants industry, gaining 51.1% over the past year [15] - The company is focusing on margin improvement, with manufacturing gross margin rising to 21.4% from 10%, and EBITDA turning positive [15][16] - However, Rocky Mountain faces liquidity risks and high-cost debt, which could impact its operational stability [17]

Key Takeaways AbbVie beat Q4 estimates and sees 9.5% revenue growth in 2026 despite Humira erosion.Skyrizi and Rinvoq delivered $26B in 2025 sales, up 40% , with over $31B projected for 2026.Aesthetics and oncology face pressure, but AbbVie's pipeline and M&A aim to drive long-term growth.AbbVie (ABBV) stock felt some downward pressure despite reporting better-than-expected fourth-quarter results on Feb. 4. AbbVie beat estimates for both earnings and sales and also issued an upbeat outlook for 2026, yet the ...

With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical companies.Allka Research's journey in the investment landscape is marked by a commitment to delivering substantial returns and strategic insights to its clients. In a world filled with complexities, Allka Re ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as we ...

Austin, United States, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Uterine Fibroid Market Size & Growth Analysis: As Per SNS Insider, The Uterine Fibroid Market size was valued at USD 5.26 Billion in 2025 and is projected to reach USD 9.43 Billion by 2033 and grow at a CAGR of 7.63% over the forecast period 2026-2033. The uterine fibroid market is expanding at a high growth rate due to the increased incidence of uterine fibroids among women of childbearing age in the world. Uterine fibroids, also known as leiomyomas, ...

Core Viewpoint - AbbVie's recent stock price decline is seen as an overreaction despite solid fourth-quarter results, with a strong long-term outlook remaining intact [1] Group 1: Financial Performance - AbbVie's fourth-quarter revenue increased by 10% year over year to $16.6 billion, driven primarily by immunology medicines Skyrizi and Rinvoq, which showed significant sales growth [2] - Humira, despite being AbbVie's third-best-selling medicine, is experiencing declining sales due to biosimilar competition after losing patent exclusivity in 2023 [4][5] Group 2: Future Growth Prospects - AbbVie projects a sales growth of 9.5% by 2026, with combined sales for Skyrizi and Rinvoq expected to exceed $31 billion, indicating better-than-expected performance [6][7] - The company has a robust pipeline with potential new approvals, including a Parkinson's disease treatment, and has made strategic investments in promising assets [8] Group 3: Dividend and Investment Appeal - AbbVie has a strong dividend track record, having increased its payout for 54 consecutive years, qualifying it as a Dividend King, which enhances its appeal for long-term income investors [9]

来源：新浪财经-鹰眼工作室 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 国家药品监督管理局药品审评中心数据显示，2026年2月15日，AbbVie Inc.的Upadacitinib口服溶液申请 已获受理，受理号为JXHB2600020。 受理号JXHB2600020药品名称Upadacitinib口服溶液药品类型化药申请类型补充申请注册分类2.2企业名 称AbbVie Inc.;AbbVie Inc.；AbbVie Ireland NL B.V.;承办日期2026年2月15日 ...

Group 1: Healthcare Industry Overview - Healthcare industry stocks serve as effective hedges against technology and growth stocks, performing well when larger stock markets do not [1] - The performance of stocks varies by sub-industry, with some pharmaceutical and biotech stocks behaving more like growth stocks [1] Group 2: Novo Nordisk - Novo Nordisk is a leading global pharmaceutical company specializing in GLP-1 drugs for weight loss and diabetes management, alongside Eli Lilly [6] - In fiscal 2025, sales for diabetes and obesity care drugs increased by 7%, with obesity care drugs seeing a 26% gain; sales growth for 2026 is projected between 5% to 13% [7] - The GLP-1 market is expected to grow to $254 billion by 2034, representing a compound annual growth rate of 17%, positioning Novo Nordisk for long-term benefits [7] - The stock is currently trading at a low valuation of 13 times earnings, priced at $49 per share, making it an attractive investment option [8] Group 3: AbbVie - AbbVie, a spinoff from Abbott Labs, has demonstrated strong defensive characteristics, rising 24% during the 2022 bear market while the S&P 500 fell by 18% [9] - AbbVie has consistently increased its dividend for 13 years since its separation from Abbott, currently offering a high yield of 3.1% [9]

经济观察网基于最新公开信息，艾伯维公司(ABBV.US)在2026年初有以下值得关注的事件进展，主要涉 及财务表现、业务板块动态及战略布局： 业绩经营情况 业务进展情况 肿瘤业务2025年收入为66.55亿美元，虽增速放缓，但新药表现突出：全球首款c-Met ADC药物Teliso-V 于2025年5月获批上市，CD3×CD20双抗Epkinly及FRαADC药物Elahere销售额分别增长85.5%和44%。公 司2025年达成超10笔交易(总金额超130亿美元)，2026年1月与荣昌生物就PD-1/VEGF双抗RC148达成独 家授权，进一步扩展肿瘤管线。 业务进展情况 2025年免疫学业务营收达304亿美元，同比增长14%。尽管Humira销售额因专利到期下滑，但新药 Skyrizi和Rinvoq需求强劲，四季度销售额分别为50亿美元和24亿美元，支撑业务过渡。 以上内容基于公开资料整理，不构成投资建议。 业务进展情况 第四季度中，Botox(保妥适)销售额达7.17亿美元，自2024年Q3以来首次实现增长，且超过市场预期。 公司通过新营销策略(如"Naturally You"活动)推动医美业务复苏，但 ...

PresentationDavid AmsellemPiper Sandler & Co., Research Division Good morning, everyone, and well, happy Friday, the 13th. And on a serious note, thanks for joining us for day 2 of our Piper's Virtual Immunology Symposium. So we're delighted to have AbbVie with us. We have Chief Scientific Officer, Roopal Thakkar. We also have Kori Wallace, who is Vice President, Immunology Development -- sorry, R&D, Immunology. So I want to make sure I didn't mangle that too badly. But thanks so much for doing this. And I ...